Exclusive radiotherapy for non-small cell lung cancer. A retrospective multicentric study

Gouders, Dominique; Maingon, P.; Paesmans, Marianne; Rodrigus, P.; Hahn, Bettina; Arnaiz, M.; Nguyễn, Thị Hiền; Landmann, Christine; Bosset, Jean-François; Danhier, S.; Houtte, Paul Van

doi:10.1016/s1507-1367(03)70991-2

Cited by 7 publications

(4 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The device used in this study addresses the challenge of respiratory motion using an image-guided real-time targeting/tracking system, resulting in a significantly reduced targeting uncertainty. In addition, a protracted fractionation schedule, which is often used to minimise the risk of radiotherapy-related pneumonitis, may result in poorer outcomes due to accelerated tumour cell repopulation during the radiation course (21,22). Precise radiotherapy by using CK uses high single doses and few segmentation numbers, together with several advantages that are absent in conventional radiotherapy.…”

Section: Discussionmentioning

confidence: 99%

Advantages of CyberKnife for inoperable stage I peripheral non-small-cell lung cancer compared to three-dimensional conformal radiotherapy

Tong

Yan

Yuan

et al. 2014

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. This study was conducted to compare the clinical curative effect and acute radiation lung reactions between CyberKnife (CK) and three-dimensional conformal radiotherapy (3DCRT) treatment for inoperable stage I peripheral non-small-cell lung cancer (NSCLC). We retrospectively analyzed 68 patients with inoperable stage I peripheral NSCLC between 2012 and 2013 in our institution. The CK patients were treated with 42-60 Gy in three fractions, while the 3DCRT patients were treated with a total of 60 Gy, at 2 Gy per fraction. The patients were followed up and the clinical outcome was evaluated according to the Response Evaluation Criteria in Solid Tumours. We assessed the presence of acute radiation pneumonitis and pulmonary function status by thoracic scan and pulmonary function tests following CK and 3DCRT treatment. The binary univariate logistic regression analysis demonstrated that treatment method and forced expiratory volume in 1 sec̸forced vital capacity (FEV1̸FVC) prior to treatment (pre-FEV1̸FVC) were the main factors affecting the risk of radiation pneumonitis. The analysis of these factors through multivariate logistic regression method demonstrated that treatment method for grade 1 and 2 [odds ratio (OR)=7.866 and 11.334, respectively) and pre-FEV1/FVC for grade 1, 2 and 3 (OR=5.062, 11.498 and 15.042, respectively) were significant factors affecting the risk of radiation pneumonitis (P<0.05). The 68 patients were divided into two subgroups using the threshold of pre-FEV1/FVC selected by the receiver operating characteristic curve. There were significant differences between the 3DCRT and CK treatment in both the pre-FEV1̸FVC <68% and ≥68% subgroups for radiation pneumonitis (P=0.023 and 0.002, respectively). There was no statistically significant change in FVC, FEV1 and carbon monoxide diffusion capacity (DCLO) in the CK group, whereas there was a decrease in DCLO in the 3DCRT group. The complete remission rate was 40 vs. 34.2% at 1 year in the CK and 3DCRT groups, respectively. In conclusion, in this cohort of patients with inoperable stage I peripheral NSCLC, CK appears to be a safe and superior alternative to conventionally fractionated radiotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Advantages of CyberKnife for inoperable stage I peripheral non-small-cell lung cancer compared to three-dimensional conformal radiotherapy

Tong

Yan

Yuan

et al. 2014

Molecular and Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…The results for conventional radiotherapy have, however, been inferior to surgery (possibly partly due to selection bias), with 2- and 5-year recurrence-free survival rates of 29% and 7%, respectively [ 24 ] .…”

Section: Primary Lung Cancermentioning

confidence: 99%

“…Traditionally, patients with stage I NSCLC who were deemed medically inoperable, or who declined surgery, were offered radical radiotherapy (treating to a total dose of 55–74 Gy in 20–37 daily fractions of 2–2.75 Gy, over a period of 4–7.5 weeks). The results for conventional radiotherapy have, however, been inferior to surgery (possibly partly due to selection bias), with 2- and 5-year recurrence-free survival rates of 29% and 7%, respectively [ 24 ] .…”

Section: Primary Lung Cancermentioning

confidence: 99%

Stereotactic ablative body radiotherapy (SABR) for primary and secondary lung tumours

Goldsmith

Gaya

2012

Cancer Imaging

View full text Add to dashboard Cite

show abstract

“…Radiotherapy provided excellent long-term local controlErdheim-Chester diseasePalliative treatment of Erdheim-Chester disease with RTMiller 22 20069EBRT provided short-term palliation in terms of pain control with most cases experiencing recurrenceSolitary plasmacytomaOutcomes and patterns of failure in solitary plasmacytomaOzsahin 23 2006258Extramedullary SP had better outcomes with moderate dose RT. Progression to myeloma remains issue with medullary diseaseDesmoid tumorsImpact of radiotherapy in treatment of desmoid tumoursBaumert 24 2006110Post-op RT significantly improved 5-year PFS (47% vs 13% for surgery alone)Non-small cell lung cancerExclusive radiotherapy for non-small cell lung cancerGouders 25 20031232 and 5 year survival- 34, 8%. 5-year local failure rate for T1,T2 - 42%/82%Urothelial renal pelvis and ureter tumorsPrognostic factors in urothelial renal pelvis and ureter tumoursOzsahin 26 1999138Survival influenced by: Karnofsky performance index, pT- and pN-classification, utereral localization, histologic grade, and existence of tumor after surgeryPapillary serous carcinomaOutcome after combined modality treatment for uterine papillary serous carcinomaGoldberg 27 2007138Radiotherapy reduced pelvic recurrence from 29% to 14%.…”

Section: Studiesmentioning

confidence: 99%

The Rare Cancer Network: Achievements from 1993 to 2012

et al. 2012

View full text Add to dashboard Cite

The Rare Cancer Network (RCN), founded in 1993, performs research involving rare tumors that are not common enough to be the focus of prospective study. Over 55 studies have either been completed or are in progress.The aim of the paper is to present an overview of the 30 studies done through the RCN to date, organized by disease site. Five studies focus on breast pathology, including sarcoma, lymphoma, phyllodes tumor, adenoid cystic carcinoma, and ductal carcinoma in situ in young women. Three studies on prostate cancer address prostatic small cell carcinoma and adenocarcinoma of young and elderly patients. Six studies on head and neck cancers include orbital and intraocular lymphoma, mucosal melanoma, pediatric nasopharyngeal carcinoma, olfactory neuroblastoma, and mucosa-associated lymphoid tissue lymphoma of the salivary glands. There were 4 central nervous system studies on patients with cerebellar glioblastoma multiforme, atypical and malignant meningioma, spinal epidural lymphoma and myxopapillary ependymoma. Outside of these disease sites, there is a wide variety of other studies on tumors ranging from uterine leiomyosarcoma to giant cell tumors of the bone. The studies done by the RCN represent a wide range of rare pathologies that were previously only studied in small series or case reports. With further growth of the RCN and collaboration between members our ability to analyze rare tumors will increase and result in better understanding of their behavior and ultimately help direct research that may improve patient outcomes.

show abstract

Exclusive radiotherapy for non-small cell lung cancer. A retrospective multicentric study

Cited by 7 publications

References 24 publications

Advantages of CyberKnife for inoperable stage I peripheral non-small-cell lung cancer compared to three-dimensional conformal radiotherapy

Advantages of CyberKnife for inoperable stage I peripheral non-small-cell lung cancer compared to three-dimensional conformal radiotherapy

Stereotactic ablative body radiotherapy (SABR) for primary and secondary lung tumours

The Rare Cancer Network: Achievements from 1993 to 2012

Contact Info

Product

Resources

About